AL amyloidosis associated with IgM monoclonal protein: A distinct clinical entity

Giovanni Palladini, Paola Russo, Tiziana Bosoni, Gabriele Sarais, Francesca Lavatelli, Andrea Foli, Letizia Zenone Bragotti, Vittorio Perfetti, Laura Obici, Franco Bergesio, Riccardo Albertini, Remigio Moratti, Giampaolo Merlini

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

IgM-associated AL amyloidosis is rare and may represent a distinct entity. Sixty (7%) of 868 consecutive AL patients referred to our center had an IgM monoclonal protein. They were significantly older than non-IgM patients (median, 67 years vs. 62 years), had a higher frequency of lymph-node involvement (25% vs. 2%) and significantly lower median proteinuria (1.2 g/24h vs. 3.4 g/24h), N-terminal pro-natriuretic peptide type-B (1177 ng/L vs. 2135 ng/L) and troponin I (0.02 ng/mL vs. 0.05 ng/mL). In IgM patients, κ light-chains were more frequent (42% vs. 23%) and the involved free light-chain concentration was lower (median 63 mg/L vs. 182 mg/L). Serum albumin and NT-proBNP were independent prognostic determinants. Response to treatment improved survival. The 14 patients who received melphalan/dexamethasone showed a 64% hematologic (complete remissions, 29%) and a 43% organ response rate. IgM-associated AL amyloidosis is a distinct entity, with less advanced organ dysfunction. Treatment with melphalan/ dexamethasone might be effective in these patients.

Original languageEnglish
Pages (from-to)80-83
Number of pages4
JournalClinical Lymphoma and Myeloma
Volume9
Issue number1
DOIs
Publication statusPublished - 2009

Fingerprint

Staphylococcal Protein A
Amyloidosis
Immunoglobulin M
Melphalan
Dexamethasone
Light
Troponin I
Brain Natriuretic Peptide
Proteinuria
Serum Albumin
Lymph Nodes
Survival
Therapeutics
Proteins

Keywords

  • Dexamethasone
  • Melphalan
  • Prednisone
  • Prognosis
  • Response
  • Waldenström
  • Waldenström's macroglobulinemia

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Hematology

Cite this

AL amyloidosis associated with IgM monoclonal protein : A distinct clinical entity. / Palladini, Giovanni; Russo, Paola; Bosoni, Tiziana; Sarais, Gabriele; Lavatelli, Francesca; Foli, Andrea; Bragotti, Letizia Zenone; Perfetti, Vittorio; Obici, Laura; Bergesio, Franco; Albertini, Riccardo; Moratti, Remigio; Merlini, Giampaolo.

In: Clinical Lymphoma and Myeloma, Vol. 9, No. 1, 2009, p. 80-83.

Research output: Contribution to journalArticle

@article{3425c9bfc5824afcb29984855f4c9366,
title = "AL amyloidosis associated with IgM monoclonal protein: A distinct clinical entity",
abstract = "IgM-associated AL amyloidosis is rare and may represent a distinct entity. Sixty (7{\%}) of 868 consecutive AL patients referred to our center had an IgM monoclonal protein. They were significantly older than non-IgM patients (median, 67 years vs. 62 years), had a higher frequency of lymph-node involvement (25{\%} vs. 2{\%}) and significantly lower median proteinuria (1.2 g/24h vs. 3.4 g/24h), N-terminal pro-natriuretic peptide type-B (1177 ng/L vs. 2135 ng/L) and troponin I (0.02 ng/mL vs. 0.05 ng/mL). In IgM patients, κ light-chains were more frequent (42{\%} vs. 23{\%}) and the involved free light-chain concentration was lower (median 63 mg/L vs. 182 mg/L). Serum albumin and NT-proBNP were independent prognostic determinants. Response to treatment improved survival. The 14 patients who received melphalan/dexamethasone showed a 64{\%} hematologic (complete remissions, 29{\%}) and a 43{\%} organ response rate. IgM-associated AL amyloidosis is a distinct entity, with less advanced organ dysfunction. Treatment with melphalan/ dexamethasone might be effective in these patients.",
keywords = "Dexamethasone, Melphalan, Prednisone, Prognosis, Response, Waldenstr{\"o}m, Waldenstr{\"o}m's macroglobulinemia",
author = "Giovanni Palladini and Paola Russo and Tiziana Bosoni and Gabriele Sarais and Francesca Lavatelli and Andrea Foli and Bragotti, {Letizia Zenone} and Vittorio Perfetti and Laura Obici and Franco Bergesio and Riccardo Albertini and Remigio Moratti and Giampaolo Merlini",
year = "2009",
doi = "10.3816/CLM.2009.n.021",
language = "English",
volume = "9",
pages = "80--83",
journal = "Clinical Lymphoma and Myeloma",
issn = "1557-9190",
publisher = "Cancer Information Group, LP",
number = "1",

}

TY - JOUR

T1 - AL amyloidosis associated with IgM monoclonal protein

T2 - A distinct clinical entity

AU - Palladini, Giovanni

AU - Russo, Paola

AU - Bosoni, Tiziana

AU - Sarais, Gabriele

AU - Lavatelli, Francesca

AU - Foli, Andrea

AU - Bragotti, Letizia Zenone

AU - Perfetti, Vittorio

AU - Obici, Laura

AU - Bergesio, Franco

AU - Albertini, Riccardo

AU - Moratti, Remigio

AU - Merlini, Giampaolo

PY - 2009

Y1 - 2009

N2 - IgM-associated AL amyloidosis is rare and may represent a distinct entity. Sixty (7%) of 868 consecutive AL patients referred to our center had an IgM monoclonal protein. They were significantly older than non-IgM patients (median, 67 years vs. 62 years), had a higher frequency of lymph-node involvement (25% vs. 2%) and significantly lower median proteinuria (1.2 g/24h vs. 3.4 g/24h), N-terminal pro-natriuretic peptide type-B (1177 ng/L vs. 2135 ng/L) and troponin I (0.02 ng/mL vs. 0.05 ng/mL). In IgM patients, κ light-chains were more frequent (42% vs. 23%) and the involved free light-chain concentration was lower (median 63 mg/L vs. 182 mg/L). Serum albumin and NT-proBNP were independent prognostic determinants. Response to treatment improved survival. The 14 patients who received melphalan/dexamethasone showed a 64% hematologic (complete remissions, 29%) and a 43% organ response rate. IgM-associated AL amyloidosis is a distinct entity, with less advanced organ dysfunction. Treatment with melphalan/ dexamethasone might be effective in these patients.

AB - IgM-associated AL amyloidosis is rare and may represent a distinct entity. Sixty (7%) of 868 consecutive AL patients referred to our center had an IgM monoclonal protein. They were significantly older than non-IgM patients (median, 67 years vs. 62 years), had a higher frequency of lymph-node involvement (25% vs. 2%) and significantly lower median proteinuria (1.2 g/24h vs. 3.4 g/24h), N-terminal pro-natriuretic peptide type-B (1177 ng/L vs. 2135 ng/L) and troponin I (0.02 ng/mL vs. 0.05 ng/mL). In IgM patients, κ light-chains were more frequent (42% vs. 23%) and the involved free light-chain concentration was lower (median 63 mg/L vs. 182 mg/L). Serum albumin and NT-proBNP were independent prognostic determinants. Response to treatment improved survival. The 14 patients who received melphalan/dexamethasone showed a 64% hematologic (complete remissions, 29%) and a 43% organ response rate. IgM-associated AL amyloidosis is a distinct entity, with less advanced organ dysfunction. Treatment with melphalan/ dexamethasone might be effective in these patients.

KW - Dexamethasone

KW - Melphalan

KW - Prednisone

KW - Prognosis

KW - Response

KW - Waldenström

KW - Waldenström's macroglobulinemia

UR - http://www.scopus.com/inward/record.url?scp=67649556687&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649556687&partnerID=8YFLogxK

U2 - 10.3816/CLM.2009.n.021

DO - 10.3816/CLM.2009.n.021

M3 - Article

C2 - 19362981

AN - SCOPUS:67649556687

VL - 9

SP - 80

EP - 83

JO - Clinical Lymphoma and Myeloma

JF - Clinical Lymphoma and Myeloma

SN - 1557-9190

IS - 1

ER -